EUDA Health Holdings LtdEUDA

Singapore-based EUDA Health Holdings Ltd. calls itself a market leader in non-invasive and preventive healthcare, but its latest 20-F filing for the year ending 31 December 2025 tells a different story: revenue of $6.8 million, net loss of $2.8 million, and a balance sheet that lists $1.7 million in assets against $6.0 million in liabilities. Shareholders are left staring at a deficit of $4.3 million, a figure that sits awkwardly beside the glossy images of “Bioenergy Capsule” and “CRISPR Gene” treatments on the company’s website. The filing also records operating cash flow of -$2.4 million and inventory shrinkage of $45,428, while R&D expense is a mere $249-less than the price of a single Singaporean bak chor mee.

What EUDA actually sells is less clear than its marketing. The company’s F-3/A filings describe it as a distributor of “non-invasive healthcare products and services,” yet the same documents note that revenue is generated primarily from “property management service fees.” The disconnect between the healthcare story and the letting-agent reality is hard to miss. Sales teams are reportedly incentivised to secure property management contracts, a detail that sits oddly beside the promise of personalised CRISPR therapies. The company’s website, meanwhile, showcases images of futuristic capsules and gene treatments, none of which are substantiated by the filings or product approvals.

The company’s latest filings-including a 424B5 dated 22 July 2026 and multiple F-3/A updates-reveal a business model built on thin air. A Share Purchase Agreement from 2022 (later amended) sets ambitious financial targets: “Revenues of at least Twenty Million One Hundred Thousand Dollars” and unspecified net income hurdles. Yet the 2025 revenue figure of $6.8 million makes those targets look less like a roadmap and more like a mirage. The same 424B5 filing notes that any transaction exceeding $200,000 triggers extra disclosure, a clause that feels increasingly elastic as the loss column deepens. The latest 13G/A filing shows no insider buying, leaving retail holders with little to cling to.

EUDA’s operating reality is captured in its cash flow: -$2.4 million for the year, with just $77,264 spent on property, plant, and equipment. Inventories stand at $2,844, down $45,428 from the prior year, while R&D is a rounding error at $249. The company’s 20-F filing labels its headquarters as a distributor of non-invasive healthcare, yet the only thing being distributed at scale appears to be shareholder disappointment. The gap between the polished platform story and the balance sheet is wider than a Singapore MRT escalator step.

The company’s latest filings do not include guidance, segment-level breakdowns, or any detail on customer concentration. The evidence rail shows no audited product approvals, clinical trial data, or regulatory milestones beyond the boilerplate language in the F-3/A documents. The company’s website and product images are marketing fluff without substantiation in the filings. The only concrete figures are the ones that hurt: $6.8 million in revenue, -$2.8 million in net loss, and a balance sheet that is underwater by $4.3 million.

For context, EUDA’s 2025 numbers are the corporate equivalent of selling stem-cell facelifts while your bank account is in ICU. The company’s filings repeatedly describe its business as a distributor of “non-invasive healthcare products and services,” yet the only revenue stream substantiated in the filings is property management fees. The disconnect between the healthcare narrative and the letting-agent reality is stark. The company’s latest 424B5 filing, for example, sets out ambitious revenue and net income targets that are not reflected in the 2025 results. The same filing notes that any transaction exceeding $200,000 triggers extra disclosure, a clause that feels increasingly elastic as the loss column grows. The latest 13G/A filing shows no insider buying, leaving retail holders with little to cling to.

What the evidence does establish is a company whose narrative outpaces its operations. The filings show a business that is small, loss-making, and reliant on property-related revenue streams rather than the futuristic healthcare platform promised on the website. The company’s latest 20-F, 424B5, and 13G/A filings are the only source of truth here-and they paint a picture of a business struggling to match its marketing to its metrics.